These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 26055935)
1. Preliminary clinical assessment of the relationship between tumor alphavbeta3 integrin and perfusion in patients studied with [(18)F]fluciclatide kinetics and [ (15)O]H 2O PET. Kenny LM; Tomasi G; Turkheimer F; Larkin J; Gore M; Brock CS; Mangar S; Aboagye EO EJNMMI Res; 2014 Dec; 4(1):30. PubMed ID: 26055935 [TBL] [Abstract][Full Text] [Related]
2. [¹⁸F]fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing αvβ 3 and α vβ 5 integrins. Mena E; Owenius R; Turkbey B; Sherry R; Bratslavsky G; Macholl S; Miller MP; Somer EJ; Lindenberg L; Adler S; Shih J; Choyke P; Kurdziel K Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1879-88. PubMed ID: 24973039 [TBL] [Abstract][Full Text] [Related]
3. Multicenter Reproducibility of 18F-Fluciclatide PET Imaging in Subjects with Solid Tumors. Sharma R; Kallur KG; Ryu JS; Parameswaran RV; Lindman H; Avril N; Gleeson FV; Lee JD; Lee KH; O'Doherty MJ; Groves AM; Miller MP; Somer EJ; Coombes CR; Aboagye EO J Nucl Med; 2015 Dec; 56(12):1855-61. PubMed ID: 26383153 [TBL] [Abstract][Full Text] [Related]
4. Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αVbeta3-integrin and αV beta5-integrin imaging agent. Battle MR; Goggi JL; Allen L; Barnett J; Morrison MS J Nucl Med; 2011 Mar; 52(3):424-30. PubMed ID: 21321268 [TBL] [Abstract][Full Text] [Related]
5. [ Sharma R; Valls PO; Inglese M; Dubash S; Chen M; Gabra H; Montes A; Challapalli A; Arshad M; Tharakan G; Chambers E; Cole T; Lozano-Kuehne JP; Barwick TD; Aboagye EO Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1239-1251. PubMed ID: 31754793 [TBL] [Abstract][Full Text] [Related]
6. In vivo alpha-V beta-3 integrin expression in human aortic atherosclerosis. Jenkins WS; Vesey AT; Vickers A; Neale A; Moles C; Connell M; Joshi NV; Lucatelli C; Fletcher AM; Spratt JC; Mirsadraee S; van Beek EJ; Rudd JH; Newby DE; Dweck MR Heart; 2019 Dec; 105(24):1868-1875. PubMed ID: 31422361 [TBL] [Abstract][Full Text] [Related]
7. Quantification of receptor-ligand binding with [¹⁸F]fluciclatide in metastatic breast cancer patients. Tomasi G; Kenny L; Mauri F; Turkheimer F; Aboagye EO Eur J Nucl Med Mol Imaging; 2011 Dec; 38(12):2186-97. PubMed ID: 21892622 [TBL] [Abstract][Full Text] [Related]
9. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. Bruehlmeier M; Roelcke U; Schubiger PA; Ametamey SM J Nucl Med; 2004 Nov; 45(11):1851-9. PubMed ID: 15534054 [TBL] [Abstract][Full Text] [Related]
10. Autoradiography screening of potential positron emission tomography tracers for asymptomatic abdominal aortic aneurysms. Tegler G; Estrada S; Hall H; Wanhainen A; Björck M; Sörensen J; Antoni G Ups J Med Sci; 2014 Aug; 119(3):229-35. PubMed ID: 24555564 [TBL] [Abstract][Full Text] [Related]
11. Multiparametric Analysis of the Relationship Between Tumor Hypoxia and Perfusion with ¹⁸F-Fluoroazomycin Arabinoside and ¹⁵O-H₂O PET. Iqbal R; Kramer GM; Verwer EE; Huisman MC; de Langen AJ; Bahce I; van Velden FH; Windhorst AD; Lammertsma AA; Hoekstra OS; Boellaard R J Nucl Med; 2016 Apr; 57(4):530-5. PubMed ID: 26659349 [TBL] [Abstract][Full Text] [Related]